Complicated Skin & Soft Tissue Infections

Outlook for patients with cSSTI worldwide
 

ZINFORO^® offers an efficacious and potent treatment for your patients with cSSTI.^1-5

• Consistently active against common causative pathogens, including MRSA
   
• Well-tolerated and efficacious treatment for most patients, including those with comorbidities

Inadequacy of first-line treatment

Around 40% of patients with cSSTI caused by mixed pathogens received inappropriate initial antimicrobial agents.^9,11

Failure of therapy

Inappropriate initial therapy may result in poor therapy outcome. Initial therapy failure is associated with higher mortality, prolonged hospitalisation and consequent increased cost burden.¹¹

Day 3 non-response rates
​​​​
In a retrospective cohort analysis of adult patients, it was observed that non-response rates at Day 3 among patients with cSSTI receiving empiric therapy with broad-spectrum antibiotics^† were high.⁹

Longer duration of hospitalisation and antibiotic treatment and higher costs

In a retrospective cohort analysis of adult patients, it was observed that non-response to initial antibiotic therapy was associated with an overall¹⁰:

• 5.4-day increase in hospital stays
   
• 3.7-day increase in the duration of antibiotic administration​​​​​​​
  ^{​​​​​​​}

*Initial antibiotic treatment modification
This is defined as the need for a change in the initial antibiotic treatment due to insufficient response, adverse reaction, interaction with other drugs, non-suitability of the initial antibiotic based on the results of microbiological tests, or changes to the antibiotic therapy or addition of further agents, alone or in combination. The presence of comorbidities is associated with higher rates of initial treatment modification in patients with cSSTI.<sup>6

†</sup>Broad-spectrum antibiotics included vancomycin, cefazolin, piperacillin-tazobactam and ampicillin-sulbactam.¹⁰
The study does not include data specific to ZINFORO^®. The study had the inherent limitations associated with a retrospective chart review because data were initially collected for clinical rather than research purposes. Hence, certain information may have been absent, incomplete or missed by data abstractors.

cSSTI, complicated skin and soft tissue infection; CAP, community-acquired pneumonia; MRSA, methicillin-resistant Staphylococcus aureus.
 

References: